Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC and Tregs in End-stage Liver Disease
NCT03460795Phase 2Unknown
- Sponsor
- Nanjing Medical University
- Start
- Jun 2020
- Primary completion
- Mar 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of mesenchymal stem cells, autologous regulatory T-lymphocytes in Liver cirrhosis (LC), sponsored by Nanjing Medical University. Status: unknown.
02
Drugs
mesenchymal stem cellsautologous regulatory T-lymphocytes
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT03460795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03460795.